Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...

A cancer drug that has already been approved by the US Food and Drug Administration (FDA) could also help people with ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Researchers have found that a pair of drugs can not only slow down Alzheimer’s disease but actually reverse it and restore memory in mice.

The harmful clumps of tau protein that build up in brains affected by Alzheimer's were reduced significantly, and the mice ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...